Drugs / Tahor
last change Jan 2018 re-read 3 minutes ago

Tahor

Developed for
hereditary spastic paraplegia

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT02314208 Comparator Jan 2015 → Sep 2017 hereditary spastic paraplegia French National Institute of Health and Medical Research Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tahor ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314208 ↗
Route Oral “Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months” NCT02314208 ↗